Systemic Antifungals of Choice in Pregnancy
Amphotericin B (preferably lipid formulations at 3-5 mg/kg/day) is the systemic antifungal of choice during pregnancy, particularly during the first trimester, due to its established safety profile and lack of teratogenic effects. 1, 2
First Trimester: Amphotericin B Only
During the first trimester, azole antifungals must be avoided due to documented teratogenic risks, including congenital craniosynostosis and skeletal abnormalities observed with high-dose fluconazole (400-800 mg/day) 2. The FDA issued a specific warning in 2011 about these risks with long-term, high-dose fluconazole exposure during early pregnancy 2.
- Lipid formulations of amphotericin B (3-5 mg/kg/day) are preferred over deoxycholate formulations due to better tolerability and established safety 1
- Amphotericin B deoxycholate (0.7-1.0 mg/kg/day) remains acceptable if lipid formulations are unavailable
- For coccidioidal meningitis specifically, intrathecal amphotericin B is recommended during the first trimester 2
Second and Third Trimesters: Azoles Become an Option
After the first trimester, azole antifungals (fluconazole or itraconazole) can be considered as the teratogenic window has passed 2. Animal data and human case reports indicate that azole-related abnormalities occur during early gestation, making post-first-trimester use reasonably safe 2.
- Fluconazole or itraconazole are the preferred azoles
- Amphotericin B remains an alternative throughout pregnancy if concerns persist 2
- For meningeal disease after the first trimester, oral azoles (fluconazole or itraconazole) are acceptable 2
Critical Caveats
Voriconazole and posaconazole should be avoided throughout pregnancy due to insufficient safety data and animal studies suggesting higher teratogenic potential 2, 3.
For women already on azole therapy who become pregnant:
- Stop azoles immediately and switch to amphotericin B for the first trimester 2
- Resume azoles after the first trimester if disease is not in remission 2
- If disease is in remission, consider discontinuing antifungals with close monitoring every 4-6 weeks 2
Breastfeeding Considerations
Fluconazole is compatible with breastfeeding, but other azoles (itraconazole, posaconazole, voriconazole) are not recommended due to accumulation in breast milk 2, 4.
Strength of Evidence
These recommendations come from high-quality IDSA guidelines (2016 for coccidioidomycosis, 2008 for blastomycosis) with strong to moderate strength ratings 1, 2. The evidence consistently prioritizes amphotericin B's proven safety record over decades of use, despite its toxicity profile and need for intravenous administration 5, 3, 6. The teratogenic concerns with azoles are well-documented through both animal studies and human case reports, making the first-trimester restriction non-negotiable 2.